PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1211736
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1211736
Preeclampsia diagnostics market size was valued at USD 1,205.7 Million in 2022, expanding at a CAGR of 4.4% from 2023 to 2030.
Preeclampsia is a severe form of the condition in pregnant women. Additionally, preeclampsia tests are required during pregnancy due to a rise in blood pressure and protein in the urine that occurs after the 20th week of pregnancy. Moreover, it may cause preterm birth and other complications such as eclampsia, organ failure, and death if not diagnosed at an early age. Furthermore increasing awareness about diagnostics procedures and disorders in pregnant women can further lead to market growth.
Market Dynamics:
The rising maternal and perinatal morbidity & mortality rates among pregnant women are set to surge the demand for the early diagnosis of preeclampsia globally. In addition, such factors are projected to drive the market growth of the preeclampsia diagnostics market. However, pregnant women's poor understanding of preeclampsia signs and symptoms is the restrain for the preeclampsia diagnostics market.
Furthermore, increasing cases of hypertension among pregnant women and increasing efforts to develop and research new tests to detect biomarkers indicating preeclampsia are opportunities projected to increase the market growth during the forecast period. COVID-19 harmed the preeclampsia diagnostics market globally. The challenges faced by market players such as the supply of raw materials decreased due to transportation irregularities. Additionally, patients suffering from covid increased, and that further impacted the preeclampsia diagnostics patient due to irregular product demand from retailers.
Segmentation Analysis:
The Global Preeclampsia Diagnostics Market is segmented on the basis of test type, product, end-use, and Region.
The market is divided into two categories based on test type: blood test, urine test, and others. The blood test segment is estimated to dominate the market. By biological testing, preeclampsia can be predicted accurately. Additionally, in the case of the early beginning of the disease, such tests help find preeclampsia both in the first and in the subsequent.
The market is divided into three categories based on product: instruments, reagents & consumables, services, and others. The service segment is expected to hold the market share during the forecast period. Services include staff salary, pathologist's collection, report printing, sample collection, and rent/EMI on the property are such expenses occurring in the diagnostic laboratory.
The market is divided into three categories based on end-use: hospitals, diagnostic centers, specialty clinics, and others. The hospital segment is expected to possess the market during the forecast period. Patients are more likely to admit to hospitals for treatment and diagnosis in case of severe preeclampsia. Additionally, by taking urine and blood samples regularly hospital segment is expected to increase.
Competitive Landscape:
Key players are focusing on launching new products which are expected to increase the market growth. Additionally, to drive market growth such players are adopting strategies including collaborations, agreements, and mergers and acquisitions. Moreover, increased awareness about preeclampsia globally, increased disorders associated with pregnancy, increase healthcare expenditures, and rapid advances in diagnostic tests can further drive market growth.
For instance, in July 2023, PerkinElmer, Inc. announced that a placental growth factor (PIGF) measurement using its DELFIA Xpress PIGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFIT - 1)/PIGF ratio using its DELFIA Xpress sFit - 1 kit (CE - IVD), are recommended for use, along with a standard clinical assessment, to confirm suspected preterm pre-eclampsia in women from 20 weeks of pregnancy onwards.
Key features of the study:
This proposed research study on preeclampsia diagnostics market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for preeclampsia diagnostics market.
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the preeclampsia diagnostics market.
Impact of COVID-19 on Preeclampsia Diagnostics Market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight preeclampsia diagnostics market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the preeclampsia diagnostics market, we have also included competitive landscape and key innovator analysis for the Air-to-Air Heat Pumps market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offersdetailed company profiling featuring major market participantswhich will help users to understand their financial information and strategic initiatives of players operating in the preeclampsia diagnostics market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
The global preeclampsia diagnostics market primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET KEY PLAYERS
MOMM Diagnostics
Roche
Siemens Healthineers
PerkinElmer
DRG INSTRUMENTS GMBH
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd
Bayer
Metabolomic Diagnostics Ltd.
Miraculins Inc.
Diabetomics, Inc.
Sera Prognostics
GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET, BY TEST TYPE
Blood Test
Urine Test
Others
GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET, BY PRODUCT
Instruments,
Reagents & Consumables
Services
Others
GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET, BY END-USE
Hospitals
Diagnostic Centers
Specialty Clinics
Others
GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA